BUZZ-Evommune shares rise as its eczema drug meets mid-stage trial targets

October 1 - ** Drug developer Evommune (EVMN.N) saw its stock price rise 4.9% in pre-market trading to $8.67

** The company announced that its experimental injectable drug EVO301 met the primary endpoint in a mid-stage clinical trial involving 70 adult patients with moderate-to-severe atopic dermatitis (commonly known as eczema)

** Reportedly, patients treated with EVO301 experienced an average reduction of 55% in severity and extent of eczema after 12 weeks, compared to only 22% in the placebo group

** About 29% of patients in the EVO301 group achieved at least a 75% improvement in eczema severity, while only 9% of the placebo group reached this level

** Dosing occurred twice during the trial: at the start and four weeks later; after the final dose, efficacy continued to improve over the following eight weeks

** 10.4% of patients in the EVO301 group reported treatment-related side effects, compared to 13.6% in the placebo group; no serious or severe treatment-related side effects were reported

** As of the previous trading day's closing, EVMN has declined 51.8% so far this year

(To assist non-native English speakers, Reuters has automated the translation of its report into several other languages. Due to the possibility of errors in automated translation or lack of needed context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for reader convenience. Reuters assumes no liability for any damage or loss resulting from the use of the automated translation function.)